Tubular MYDGF Slows Progression of Chronic Kidney Disease by Maintaining Mitochondrial Homeostasis
Advanced Science · 2025
DOI: 10.1002/advs.202409756 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Xiaohan Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Mitochondria, Kidney Tubules. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Mitochondrial dysfunction is a key event driving the maladaptive repair of tubular epithelial cells during the transition from acute kidney injury to chronic kidney disease (CKD). Therefore, identifying potential targets involved in mitochondrial dysfunction in tubular epithelial cells is clinically important. Myeloid‐derived growth factor (MYDGF), a novel secreted protein, plays important roles in multiple cardiovascular diseases, but the function of MYDGF in tubular epithelial cells remains unknown. In the present study, it is found that MYDGF expression is significantly reduced in the cortex of the kidney, especially in the proximal tubules, from mice with CKD. Notably, lower expression of MYDGF is observed in tubules from patients with CKD and the level of MYDGF correlated with key factors related to kidney fibrosis and estimated glomerular filtration rate (eGFR) in patients with CKD. Tubule‐specific deletion of Mydgf exacerbates kidney injury in mice with CKD; however, Mydgf overexpression attenuates kidney fibrosis by remodeling mitochondrial homeostasis in tubular epithelial cells. Mechanistically, renal tubular MYDGF positively regulates the expression of isocitrate dehydrogenase 2 (IDH2), restores mitochondrial homeostasis, and slows CKD progression. Thus, this study indicates that MYDGF derived from tubules may be an effective therapeutic strategy for patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, 250012, China.
- Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, China.
- Jincheng General Hospital, Jincheng, 048006, China.
- Department of Organ Transplantation, Qilu Hospital of Shandong University, Jinan, 250012, China.
- National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital…
ORCID-Profile: Min Liu
Förderung
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
Zitieren
APA
Liu, X., Zhang, Y., Wang, Y., Yang, Y., Qiao, Z., Zhan, P., Jin, H., Xu, Q., Tang, W., Sun, Y., Zhang, Y., Yi, F., & Liu, M. (2025). Tubular MYDGF Slows Progression of Chronic Kidney Disease by Maintaining Mitochondrial Homeostasis. Advanced Science. https://doi.org/10.1002/advs.202409756
Vancouver
Liu X, Zhang Y, Wang Y, Yang Y, Qiao Z, Zhan P, et al. Tubular MYDGF Slows Progression of Chronic Kidney Disease by Maintaining Mitochondrial Homeostasis. Advanced Science. 2025. doi:10.1002/advs.202409756
BibTeX
@article{Liu2025,
author = {Liu, Xiaohan and Zhang, Yang and Wang, Youzhao and Yang, Yujie and Qiao, Zhe and Zhan, Ping and Jin, Huiying and Xu, Qianqian and Tang, Wei and Sun, Yu and Zhang, Yan and Yi, Fan and Liu, Min},
title = {Tubular MYDGF Slows Progression of Chronic Kidney Disease by Maintaining Mitochondrial Homeostasis},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202409756}
}
EUVIMED